好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cereset Research Improves Autonomic Function in Stressed Healthcare Workers: A Randomized Clinical Trial
Neuromuscular and Clinical Neurophysiology (EMG)
P5 - Poster Session 5 (5:30 PM-6:30 PM)
3-013
To evaluate Cereset Research™ (CR), effect on autonomic regulation in healthcare workers (HCW).   
CR is a closed-loop, acoustic stimulation neurotechnology which improved autonomic regulation in other populations. This trial evaluates CR effect on autonomic regulation in stressed HCW.
Adult HCW with stress (Perceived Stress Scale, PSS, of ≥14) enrolled in this waitlist controlled randomized trial. Following consent and baseline measure collection, participants were randomized to early intervention (EI), with 4, 36-minute sessions of CR (tones linked to brainwaves) or a waitlist control condition (WC). Control participants could opt to receive the CR intervention following V3 assessment. Outcomes were collected at 10-24 days (V2; immediate post-intervention for EI group). Primary outcome assessment occurred 4-7 weeks (V3) later. The study was powered to detect a moderate clinically significant between-group difference in change in the PSS score at V3 (primary outcome). Exploratory outcomes included change in heart rate variability (HRV) assessed as standard deviation of beat-to-beat interval (SDNN), root mean square of successive differences (rMSSD), and the ratio of low frequency to high frequency power (LF/HF). Higher SDNN and rMSSD indicates enhanced parasympathetic tone and higher LF/HF indicates higher sympathetic tone. Repeated measures ANOVA analyzed the longitudinal changes between groups.
Of 144 HCW enrolled, 130 completed HRV data collection for all three visits (84.6% female, mean age 44.0 [SD 10.96]. The adjusted between group differences at V3 in SDNN (milliseconds) were EI 4.8 (SE 1.6), WC 0.3 (1.6) (p=0.049); rMSSD (milliseconds) EI 9.5 (SE 1.5), WC -0.4 (1.5) (p<0.0001); LF/HF ratio: EI -0.48 (SE 0.2), WC 0.19 (0.2) (p=0.018). 
This randomized, waitlist-controlled trial of noninvasive acoustic neuromodulation showed a significant increase in parasympathetic mediated heart rate variability and reduction in sympathetic tone to the heart among stressed HCW. This intervention may be promising for implementation in health systems to improve HCW autonomic regulation.
Authors/Disclosures
Hossam A. Shaltout, PhD (Wake Forest School of Medicine)
PRESENTER 		Dr. Shaltout has nothing to disclose.
Catherine Tegeler (Wake Forest Sch of Med, Neurology) Ms. Tegeler has nothing to disclose.
Gregory Russell (Department of Biostatistics and Data Science) No disclosure on file
Kenzie Brown No disclosure on file
Dawn Kellar No disclosure on file
Suzanne Danhauer (Wake Forest University School of Medicine) No disclosure on file
Heidi Munger Clary, MD, MPH (Wake Forest University School of Medicine) Dr. Munger Clary has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Xenon. Dr. Munger Clary has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prova 好色先生. Dr. Munger Clary has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia Open. Dr. Munger Clary has stock in HCA Healthcare. Dr. Munger Clary has stock in Eli Lilly. Dr. Munger Clary has stock in Procter and Gamble. Dr. Munger Clary has stock in CVS. Dr. Munger Clary has stock in Johnson and Johnson. Dr. Munger Clary has stock in Novartis. Dr. Munger Clary has stock in Danahauer. The institution of Dr. Munger Clary has received research support from National Institute of Health. The institution of Dr. Munger Clary has received research support from Suzanne Marcus Collins Foundation. The institution of Dr. Munger Clary has received research support from Eysz, Inc. The institution of Dr. Munger Clary has received research support from Department of Defense. The institution of Dr. Munger Clary has received research support from Duke Endowment. Dr. Munger Clary has received personal compensation in the range of $500-$4,999 for serving as a speaker, Psychiatry Commission member with International League Against Epilepsy. Dr. Munger Clary has received personal compensation in the range of $0-$499 for serving as a Faculty with J. Kiffin Penry Epilepsy 好色先生 Programs. Dr. Munger Clary has a non-compensated relationship as a advisor, potential site PI with Liva Nova that is relevant to AAN interests or activities.
Charles H. Tegeler, MD (Wake Forest School of Medicine) Dr. Tegeler has nothing to disclose.